Andre C. Schuh

Also affiliated with Princess Margaret Cancer Centre

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial”.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00494-0

N/A

4.0DataRank · unranked

193 citations

Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton +12 more

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet Haematology(2020)10.1016/s2352-3026(20)30205-2

N/A

0.688DataRank · unranked

97 citations

Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal +47 more